Bone treatment startup raises $5.5 M in Series A financing, names pharmaceutical leader William Boyle as CEO
Novosteo Inc. will use funding to advance development of the first-ever targeted bone anabolic agent NOV004 for the treatment of bone fractures, other bone diseases and support Phase 1 clinical trials.